Skip to main content

Table 1 Clinical characteristics of patients with HFpEF and non-HF patients in HCM

From: Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy

Parameters All (n=1178) HFpEF# (n=513) Non-HF# (n=665) P value*
Age at evaluation (years) 49±14 50±14 48±14 0.146
Female 415 (35.2) 229 (44.6) 186 (28.0) < 0.001
MWT (mm) 23 (20–26) 24 (21–28) 22 (19–25) < 0.001
LVEF (%) 68±8 69±7 68±6 0.027
LVedd (mm) 44±6 43±6 44±5 < 0.001
Unexplained syncope 149 (12.6) 75 (14.6) 74 (11.1) 0.070
Atrial fibrillation 230 (19.5) 140 (27.3) 90 (13.5) < 0.001
Maximal LVOT gradient 44 (10–80) 64 (29–94) 25 (8–67) < 0.001
NT-proBNP 988.0 (494.1–1934.4) 1807.0 (1225.0–2892.6) 536.8 (304.6–796.8) < 0.001
NYHA class     
 I 385 (32.7) 0 (0.0) 385 (57.9) < 0.001
 II 514 (43.6) 313 (61.0) 201 (30.2) < 0.001
 III/IV 279 (23.7) 200 (39.0) 79 (11.9) < 0.001
Medicine treatment     
 Beta-blockers 861 (73.1) 387 (75.4) 474 (71.3) 0.110
 ACEI/ARBs 232 (19.7) 70 (13.6) 162 (24.4) < 0.001
 Calcium-channel blocker 230 (19.5) 87 (17.0) 143 (21.5) 0.051
 Diuretic 269 (22.8) 160 (31.2) 109 (16.4) < 0.001
  1. In our cohort, the data on the maximal LVOT gradient were not available in 15 (1.3%) patients and the missing values were imputed using the median.
  2. Values are presented as the mean±SD, median (interquartile range) or n (%)
  3. AHA American Heart Association, LVedd left ventricular end-diastolic dimension, LVEF left ventricular ejection fraction, LVOT left ventricular outflow tract, MWT maximal wall thickness, NT-proBNP N-terminal pro-brain natriuretic peptide, NYHA New York Heart Association
  4. #Heart failure phenotypes were identified using AHA criteria
  5. *Comparison between patients with HFpEF and non-HF patients